Moriyama T, et al. - Researchers investigated if sertraline (Ser, selective serotonin reuptake inhibitor) decreases albuminuria levels through interfering with albumin endocytosis via caveolae into glomerular endothelial cells (GEnCs) and podocytes as a new treatment for glomerulonephritis. Via immunofluorescence and western blot analyses, the assessment of albumin and caveolin-1 expression levels was done following the treatment of cells with Ser. They also used a puromycin aminonucleoside (PAN)-induced nephrotic syndrome mouse model (PAN mice) treated with or without Ser, to know albuminuria level via histology. Findings revealed that Ser caused a decrease in albuminuria by interfering with albumin internalization through the caveolae into GEnCs and podocytes. This suggests that dynamin inhibitors may afford a new treatment choice for decreasing albuminuria in glomerulonephritis.